Compare NextEra Energy, Inc. (NEE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs TG Therapeutics Inc — how do they compare? NextEra Energy, Inc. trades at $83.15 (market cap $174.87B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: NextEra Energy, Inc. is far larger — about 20.5× TG Therapeutics Inc's market cap, and NextEra Energy, Inc. pays a 2.97% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NEE | TGTX | |
|---|---|---|
Market Cap | $174.87B | $8.53B |
Sector | Utilities | Health |
52-Week High | $97.88 | $59.06 |
52-Week Low | $69.83 | $26.94 |
Enterprise Value | $282.20B | $8.74B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $83.83, showing modest daily gains of 0.48% amid a bearish technical outlook. The company demonstrates strong fundamentals with $27.4B revenue and 32.4% net margins in 2025, though recent Q4 2025 earnings missed expectations. Positive developments include securing a $1.9B DOE loan for nuclear plant restart and ongoing investor meetings. Analyst consensus remains strongly bullish with a $100.20 price target, representing 20% upside potential from current levels.
NEE presents a compelling long-term investment case with robust profitability and strategic growth initiatives in renewable energy and nuclear power. However, investors face risks from rising debt levels (47.6% debt-to-asset ratio) and recent technical weakness. The stock's current discount to analyst targets offers opportunity, but requires monitoring of execution on growth projects and debt management.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
